REBINYN DIN 02532964
Status: Marketed
Holder: NOVO NORDISK CANADA INC
Health Canada record
| Active ingredient(s) | COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED 3000 UNIT |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | B02BD04 COAGULATION FACTOR IX |
| Original market date | 13-Feb-2024 |
| Current status date | 13-Feb-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novo Nordisk Canada Inc — licence 100175, currently licensed, last inspection rating C (2023-02-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02470187 | REBINYN | NOVO NORDISK CANADA INC | Powder For Solution | COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED 500 UNIT | Marketed |
| 02470268 | REBINYN | NOVO NORDISK CANADA INC | Powder For Solution | COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED 1000 UNIT | Marketed |
| 02470276 | REBINYN | NOVO NORDISK CANADA INC | Powder For Solution | COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED 2000 UNIT | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29516 | 2022-11-22 | Supplement to a New Drug Submission (SNDS) | Addition of a new strength |